Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

107

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo
DRUG: Exenatide
DRUG: Dapagliflozin
DRUG: Exenatide and Dapagliflozin

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

[object Object]